N-aroyl cyclic amine derivatives as orexin receptor antagonists

Details N-aroyl cyclic amine derivatives as orexin receptor antagonists N-aroyl cyclic amine derivatives as orexin receptor antagonists

2011-03-01

2011-03-01

Morris, Patricia L (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S309000, C514S310000, C546S141000, C546S143000, C546S145000, C546S146000

Reexamination Certificate

active

07897618

ABSTRACT:
Disclosed are N-aroyl cyclic amine derivatives having the formula:where the variables are as define herein, and their use as pharmaceuticals, specifically as orexin receptor antagonists.

REFERENCES:
patent: 5547978 (1996-08-01), Christensen et al.
patent: 6326379 (2001-12-01), Macor et al.
patent: 6677354 (2004-01-01), Branch et al.
patent: 6706720 (2004-03-01), Atwal et al.
patent: 2004/0143115 (2004-07-01), Branch et al.
patent: 2004/0192673 (2004-09-01), Gaillard et al.
patent: 2004/0215014 (2004-10-01), Chan et al.
patent: 2006/0040937 (2006-02-01), Branch et al.
patent: WO 99/09024 (1999-02-01), None
patent: WO 00/47576 (2000-08-01), None
patent: WO 00/47580 (2000-08-01), None
patent: WO 01/96302 (2001-12-01), None
Brisbare-Roch et al.Nature Medicine, 13(2): 150-155 (2007).
Hagan et al.Proc. Natl. Acad. Sci. USA., 96: 10911-10916 (1999).
Piper et al.Eur. J. Neurosci., 12: 726-730 (2000).
Patani et al.Chem. Rev., 96: 3147-3176 (1996).
Boutrel et al.PNAS, 102(52): 19168-19173 (2005).
Borglund et al.Neuron, 49: 589-601 (2006).
Harris et al.Nature, 437: 556-559 (2005).
Mori et al.Chem. Pharm. Bull., 32(10): 3840-3847 (1984).
Defoin et al.Helv. Chim. Acta, 75(1): 109-123 (1992).
Lang et al.J. Med. Chem., 47: 1153-1160 (2004).
Smart et al.Euro. J. Pharm., 440: 199-212 (2002).
Langmead et al.Br. J. Pharmacol., 141: 340-346 (2004).
Porter et al.Bioorg. &Med. Chem. Lett., 11: 1907-1910 (2001).
Duxon et al.Psychopharmacology, 153: 203-209 (2001).
White et al.Peptides, 26: 2331-2338 (2005).
Ishii et al.Behav. Brain Res., 160: 11-24 (2005).
Ishii et al.Behav. Brain Res., 157: 331-341 (2005).
Ishii et al.Physiol.&Behav., 81: 129-140 (2004).
Smith et al.Neurosci. Lett., 341: 256-258 (2003).
Haynes et al.Regulatory Peptides, 104: 153-159 (2002).
Bingham et al.Pain, 92: 81-90 (2001).
Rodgers et al.Eur. J. Neurosci., 13: 1444-1452 (2001).
Smart et al.Br. J. Pharmacol., 132: 1179-1182 (2001).
Jones et al.Psychopharmacology, 153: 210-218 (2001).
Haynes et al.Regulatory Peptides, 96: 45-51 (2000).
Rodgers et al.Neuropeptides, 36(5): 303-325 (2002).
Patini et al.,Chem. Rev., 96: 3147-3148 (1996).
Kilduff et al.Trends Neurosci., 23: 359-365 (2000).
Taheri et al.Annu. Rev. Neurosci., 25: 283-313 (2002).
Cai et al.Expert Opin. Ther. Patents, 16(5): 631-646 (2006).

Affiliated with

Also associated with

Rating

N-aroyl cyclic amine derivatives as orexin receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with N-aroyl cyclic amine derivatives as orexin receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and N-aroyl cyclic amine derivatives as orexin receptor antagonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2700490